Scholarlink

Background <p>Avoidant/restrictive food intake disorder (ARFID) is a&#xa0;diagnosis newly included in the International Classification of Diseases 11 (ICD-11). Although ARFID is already included in the Diagnostic and Statistical Manual of Mental Disorders 5 (DSM 5), there is hardly any reliable knowledge about the disease and with respect to possible therapeutic approaches. This is also true for treatment approaches, therefore there are no recommendations for action for medical professionals.</p> Objective <p>The aim of this article is to provide an overview of the treatment options for ARFID currently described in published studies.</p> Method <p>In order to achieve this aim, studies identified through a&#xa0;systematic review are compared and analyzed. The results are illustrated by potential treatment plans based on selected case studies.</p> Results <p>Of the 25&#xa0;studies found in the review 12&#xa0;used cognitive behavioral therapy (CBT) and 8&#xa0;applied family-based therapy (FBT), of which 3&#xa0;had an extra module called unified protocol for transdiagnostic treatment of emotional disorders in children/adolescents (UP-C/A). The remaining five studies applied both treatment concepts.</p> Conclusion <p>Case studies were predominantly examined, which support the hypothesis that ARFID research is still in the early stages of development. Hence, hardly any randomized, controlled studies have been published that examined the feasibility, acceptability and effectiveness of ARFID treatment. To propose recommendations for action randomized controlled studies and research must be carried out with respect to the ARFID patient group.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

„Avoidant/restrictive food intake disorder“

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月1日

查看全文
  • Sandra Pahr-Hosbach,
  • Claudia Miersch,
  • Anna-Christina Euringer

摘要

Background

Avoidant/restrictive food intake disorder (ARFID) is a diagnosis newly included in the International Classification of Diseases 11 (ICD-11). Although ARFID is already included in the Diagnostic and Statistical Manual of Mental Disorders 5 (DSM 5), there is hardly any reliable knowledge about the disease and with respect to possible therapeutic approaches. This is also true for treatment approaches, therefore there are no recommendations for action for medical professionals.

Objective

The aim of this article is to provide an overview of the treatment options for ARFID currently described in published studies.

Method

In order to achieve this aim, studies identified through a systematic review are compared and analyzed. The results are illustrated by potential treatment plans based on selected case studies.

Results

Of the 25 studies found in the review 12 used cognitive behavioral therapy (CBT) and 8 applied family-based therapy (FBT), of which 3 had an extra module called unified protocol for transdiagnostic treatment of emotional disorders in children/adolescents (UP-C/A). The remaining five studies applied both treatment concepts.

Conclusion

Case studies were predominantly examined, which support the hypothesis that ARFID research is still in the early stages of development. Hence, hardly any randomized, controlled studies have been published that examined the feasibility, acceptability and effectiveness of ARFID treatment. To propose recommendations for action randomized controlled studies and research must be carried out with respect to the ARFID patient group.